The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or Arrestin3 effectively

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Al Sabah, Suleiman ^a   Al Fulaij, Munya ^a   Shaaban, Ghina ^a   Ahmed, Hanadi A ^a   Mann, Rosalind J ^b   Donnelly, Dan ^b   Bünemann, Moritz ^c   Krasel, Cornelius ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARRESTIN 3; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR KINASE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; ADRBK1 PROTEIN, HUMAN; ARRESTIN3; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; PROTEIN BINDING; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; INTERNALIZATION; LUCIFERASE ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CHO CELL LINE; CRICETULUS; GENETICS; HAMSTER; HEK293 CELL LINE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; ARRESTINS; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, TYPE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEK293 CELLS; HUMANS; PROTEIN BINDING; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84907000576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106890     Document Type: Article

References (37)

1. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
2. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409- 1439.
3. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S (2011) Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34 Suppl 2: S251-257.
4. Ahren B (2011) The future of incretin-based therapy: novel avenues-novel targets. Diabetes Obes Metab 13 Suppl 1: 158-166.
5. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, et al. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307.
6. Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60: 470-512.
7. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819-837.
8. Ussher JR, Drucker DJ (2012) Cardiovascular biology of the incretin system. Endocr Rev 33: 187-215.
9. McIntosh CH, Widenmaier S, Kim SJ (2010) Pleiotropic actions of the incretin hormones. Vitam Horm 84: 21-79.
10. Krasel C, Bunemann M, Lorenz K, Lohse MJ (2005) Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem 280: 9528-9535.
11. Luttrell LM, Gesty-Palmer D (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62: 305-330.
12. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, et al. (2008) Beta- Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci U S A 105: 6614-6619.
13. Talbot J, Joly E, Prentki M, Buteau J (2012) beta-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide- 1 in pancreatic beta INS832/13 cells. Mol Cell Endocrinol 364: 65-70.
14. Jorgensen R, Kubale V, Vrecl M, Schwartz TW, Elling CE (2007) Oxyntomodulin differentially affects glucagon-like peptide-1 receptor betaarrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther 322: 148-154.
15. Seifert R, Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366: 381-416.
16. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW (2003) High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 17: 2201-2210.
17. Huang Y, Wilkinson GF, Willars GB (2010) Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br J Pharmacol 159: 237-251.
18. Whitaker GM, Lynn FC, McIntosh CH, Accili EA (2012) Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization. PLoS One 7: e32675.
19. Krasel C, Zabel U, Lorenz K, Reiner S, Al-Sabah S, et al. (2008) Dual role of the beta2-adrenergic receptor C terminus for the binding of beta-arrestin and receptor internalization. J Biol Chem 283: 31840-31848.
20. Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS (2007) Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function. J Pharmacol Exp Ther 321: 298-307.
21. Akhtar S, Yousif MH, Dhaunsi GS, Sarkhouh F, Chandrasekhar B, et al. (2013) Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. PLoS One 8: e67813.
22. Engelhardt S, Grimmer Y, Fan GH, Lohse MJ (2001) Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice. Mol Pharmacol 60: 712-717.
23. Holst JJ, Deacon CF (2013) Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab 24: 145-152.
24. Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, et al. (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5: 209-151.
25. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS (2010) Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther 332: 274-280.
26. Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ (2013) An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol Ther 139: 359-391.
27. Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, et al. (1998) Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41: 1194-1198.
28. Torekov SS, Harslof T, Rejnmark L, Eiken P, Jensen JB, et al. (2014) A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 99: E729-733.
29. Ravier MA, Leduc M, Richard J, Linck N, Varrault A, et al. (2014) beta- Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice. Diabetologia 57: 532-541.
30. Jorgensen R, Martini L, Schwartz TW, Elling CE (2005) Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: A high-affinity receptor phenotype. Mol Endocrinol 19: 812-823.
31. Syme CA, Zhang L, Bisello A (2006) Caveolin-1 regulates cellular trafficking and function of the glucagon-like Peptide 1 receptor. Mol Endocrinol 20: 3400- 3411.
32. Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, et al. (2012) Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces Gprotein- coupled receptor heteromer formation. Mol Pharmacol 81: 309-318.
33. Tseng CC, Zhang XY (2000) Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling. Endocrinology 141: 947-952.
34. Jorgensen R, Norklit Roed S, Heding A, Elling CE (2011) Beta-arrestin2 as a competitor for GRK2 interaction with the GLP-1 receptor upon receptor activation. Pharmacology 88: 174-181.
35. Vilardaga JP, Bunemann M, Krasel C, Castro M, Lohse MJ (2003) Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol 21: 807-812.
36. Ceperuelo-Mallafre V, Duran X, Pachon G, Roche K, Garrido-Sanchez L, et al. (2014) Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab 99: E908-919.
37. Pierce KL, Lefkowitz RJ (2001) Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2: 727-733.